Sermorelin Dosage Guide

Sermorelin acetate is the biologically active fragment (amino acids 1-29) of the 44-amino acid GHRH molecule. It was previously FDA-approved as Geref® for the diagnosis of GH deficiency in children, though it was withdrawn from the market in 2008 for commercial reasons, not safety concerns.

Sermorelin stimulates the anterior pituitary to produce and secrete growth hormone in a physiologic, pulsatile manner. Unlike exogenous GH, sermorelin preserves the natural feedback mechanisms of the hypothalamic-pituitary axis, making it a preferred research compound for GH optimization studies.

Clinical studies and compounding pharmacy protocols have established the following dose ranges:

The standard clinical dose is 200–300 mcg administered subcutaneously at bedtime. Some protocols use higher doses (up to 1 mg) for short loading phases, though evidence supporting doses above 500 mcg is limited.

Sermorelin is administered once daily at bedtime to synergize with the body's natural nocturnal GH surge. Timing considerations:

• Inject 30–60 minutes before sleep on an empty stomach (2+ hours after last meal).
• Avoid eating after injection — carbohydrates and fats blunt GH release.
• Consistency is key — daily administration at the same time produces the best results.

Cycling: Sermorelin is typically used for 3–6 months continuously, followed by a 1–2 month break. Some protocols run for 6–12 months with periodic GH/IGF-1 monitoring.

• Step 1: Swab vial stoppers with alcohol.
• Step 2: For a 9 mg vial, add 3 mL BAC water to yield 3 mg/mL (300 mcg per 0.1 mL).
• Step 3: Aim the stream against the glass wall.
• Step 4: Gently swirl until fully dissolved.
• Step 5: Store at 2–8°C. Use within 21 days.

Administer subcutaneously using a 29–31 gauge insulin syringe. The abdominal area is preferred for injection. Sermorelin is fragile — avoid heat exposure and vigorous shaking.

• 100–200 mcg: Well-tolerated. Possible injection site reaction (redness, swelling), transient flushing.
• 200–300 mcg: Occasional headache, dizziness, mild water retention, vivid dreams.
• 300–500 mcg: Increased frequency of headache and flushing. Possible hyperactivity at injection site. Rare reports of nausea.

Sermorelin has a strong safety record from its FDA-approved period. Serious adverse events are rare at standard research doses.

Sermorelin is used for research purposes and is available through compounding pharmacies under medical supervision.

Sermorelin should not be used in subjects with active malignancies. Monitor GH and IGF-1 levels periodically to ensure they remain within physiologic ranges. Consult a healthcare provider for proper medical oversight.